261 related articles for article (PubMed ID: 26519601)
1. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis.
Oró D; Yudina T; Fernández-Varo G; Casals E; Reichenbach V; Casals G; González de la Presa B; Sandalinas S; Carvajal S; Puntes V; Jiménez W
J Hepatol; 2016 Mar; 64(3):691-8. PubMed ID: 26519601
[TBL] [Abstract][Full Text] [Related]
2. Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease.
Carvajal S; Perramón M; Oró D; Casals E; Fernández-Varo G; Casals G; Parra M; González de la Presa B; Ribera J; Pastor Ó; Morales-Ruíz M; Puntes V; Jiménez W
Sci Rep; 2019 Sep; 9(1):12848. PubMed ID: 31492960
[TBL] [Abstract][Full Text] [Related]
3. Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson's disease in rats.
Hegazy MA; Maklad HM; Samy DM; Abdelmonsif DA; El Sabaa BM; Elnozahy FY
Neurochem Int; 2017 Sep; 108():361-371. PubMed ID: 28527632
[TBL] [Abstract][Full Text] [Related]
4. Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes.
Carvajal S; Perramón M; Casals G; Oró D; Ribera J; Morales-Ruiz M; Casals E; Casado P; Melgar-Lesmes P; Fernández-Varo G; Cutillas P; Puntes V; Jiménez W
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783479
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective effect of cerium oxide nanoparticles in monocrotaline rat model of pulmonary hypertension: A possible implication of endothelin-1.
Nassar SZ; Hassaan PS; Abdelmonsif DA; ElAchy SN
Life Sci; 2018 May; 201():89-101. PubMed ID: 29588134
[TBL] [Abstract][Full Text] [Related]
7. Cerium Oxide Nanoparticles Attenuate Oxidative Stress and Inflammation in the Liver of Diethylnitrosamine-Treated Mice.
Adebayo OA; Akinloye O; Adaramoye OA
Biol Trace Elem Res; 2020 Jan; 193(1):214-225. PubMed ID: 30993490
[TBL] [Abstract][Full Text] [Related]
8. Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats.
Ribera J; Rodríguez-Vita J; Cordoba B; Portolés I; Casals G; Casals E; Jiménez W; Puntes V; Morales-Ruiz M
PLoS One; 2019; 14(6):e0218716. PubMed ID: 31233564
[TBL] [Abstract][Full Text] [Related]
9. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis.
Parra-Robert M; Casals E; Massana N; Zeng M; Perramón M; Fernández-Varo G; Morales-Ruiz M; Puntes V; Jiménez W; Casals G
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31470518
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Potential of Cerium Oxide Nanoparticles for the Treatment of Peritonitis Induced by Polymicrobial Insult in Sprague-Dawley Rats.
Manne ND; Arvapalli R; Nepal N; Thulluri S; Selvaraj V; Shokuhfar T; He K; Rice KM; Asano S; Maheshwari M; Blough ER
Crit Care Med; 2015 Nov; 43(11):e477-89. PubMed ID: 26327202
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MAP kinase/NF-kB mediated signaling and attenuation of lipopolysaccharide induced severe sepsis by cerium oxide nanoparticles.
Selvaraj V; Nepal N; Rogers S; Manne ND; Arvapalli R; Rice KM; Asano S; Fankhanel E; Ma JJ; Shokuhfar T; Maheshwari M; Blough ER
Biomaterials; 2015 Aug; 59():160-71. PubMed ID: 25968464
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory properties of cerium oxide nanoparticles.
Hirst SM; Karakoti AS; Tyler RD; Sriranganathan N; Seal S; Reilly CM
Small; 2009 Dec; 5(24):2848-56. PubMed ID: 19802857
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
14. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
15. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
16. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension.
Duong HT; Dong Z; Su L; Boyer C; George J; Davis TP; Wang J
Small; 2015 May; 11(19):2291-304. PubMed ID: 25641921
[TBL] [Abstract][Full Text] [Related]
17. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
18. Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague-Dawley rats.
Manne ND; Arvapalli R; Nepal N; Shokuhfar T; Rice KM; Asano S; Blough ER
J Nanobiotechnology; 2015 Oct; 13():75. PubMed ID: 26498824
[TBL] [Abstract][Full Text] [Related]
19. Cerium Oxide Nanoparticles Reduce Microglial Activation and Neurodegenerative Events in Light Damaged Retina.
Fiorani L; Passacantando M; Santucci S; Di Marco S; Bisti S; Maccarone R
PLoS One; 2015; 10(10):e0140387. PubMed ID: 26469804
[TBL] [Abstract][Full Text] [Related]
20. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
